X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

The documents relate to contracts the department entered into between March 2007 and October 2020, totaling an estimated $3 ...

XoZymes replaces traditional chemical production methods with an approach that integrates widely available feedstocks like sugar and biomass with advanced enzymes engineered to thrive outside living ...